Velaglucerase Beta for Injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Company
- CANbridge (Shanghai) Life Sciences Ltd.
- Medicine type
- Biologic
- Therapeutic area
- Other & rare diseases
- Indications recorded in the public source
- Long-term enzyme replacement therapy (ERT) for adolescents aged 12 years and older and adults with type I or type III Gaucher disease.
- Indication source and scope
- Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
- Prescribing-information limitations
- Indications checked against an official public submission. The full original prescribing information is still unavailable.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Commercial insurance list only; not included in basic insurance
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Listed under commercial health insurance, not paid by the basic medical insurance fund. Actual commercial insurance coverage depends on the policy contract.
- Insurance verification notes
- Exact match in the commercial insurance list; the basic insurance notice excludes payment.
Sources
- https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=da298734646c4a4ca1b5ca612ee23fb1.pdf
- https://www.nhsa.gov.cn/attach/Ypsnsp2025/YPSW202500223/YPSW202500223.pdf
Open the interactive record, public price references and discussions